SRPT Stock Sees Largest Daily Increase in Almost 8 Years Following Rare Muscle Disorders Study, Yet Wall Street Remains Skeptical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Source: stocktwits
Sarepta's Promising Data: Analysts have noted that Sarepta Therapeutics' data appears promising, but the company is awaiting additional data in the second half of 2026 to better assess its programs in neuromuscular diseases.
Stock Performance: Shares of Sarepta Therapeutics rose 35% despite concerns raised by Wall Street regarding early clinical results for two of its programs, indicating a mixed market sentiment.
Limited Early Data: The initial data released for Sarepta's treatments, while showing potential for muscle concentration, is considered very limited, and safety remains an open debate among analysts.
Market Sentiment Shift: Retail sentiment around Sarepta's stock has shifted from "bullish" to "extremely bullish" over the past 24 hours, despite the stock having dropped 68% over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to rise
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 16.960
Low
5.00
Averages
20.80
High
45.00
Current: 16.960
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Investment Environment Improves
- Improved Market Conditions: Biotech investors are experiencing a friendlier macro environment not seen in years, with stabilizing interest rates, increased FDA activity, and pharmaceutical companies holding billions in cash while facing patent cliffs, creating a favorable backdrop for smaller biotech firms.
- Schrödinger's Growth Potential: Schrödinger (SDGR) is guiding for a 10% to 15% growth in annual contract value (ACV) for 2026, reaching between $218 million and $228 million, showcasing strong growth potential in drug discovery, while reporting total revenue of $256 million for 2025, making it one of the few profitable AI-driven biotech companies.
- Sarepta's Commercial Challenges: Sarepta (SRPT) reported net product revenue of $1.86 billion for 2025, and despite ongoing safety controversies surrounding its Elevidys gene therapy, it maintains a 2026 revenue guidance of $1.2 billion to $1.4 billion, demonstrating a robust commercial foundation in the Duchenne muscular dystrophy market.
- NRX's Regulatory Progress: NRX Pharmaceuticals (NRXP) has received positive feedback from the FDA regarding its lead drug candidate, with a potential decision expected this summer, and while it faces financing and execution risks, its focus on severe depression treatments is attracting increasing investor interest.
See More
Analysis of Biotech Companies' Prospects
- AI-Driven Drug Discovery: Schrödinger reported total revenue of $256 million in 2025, with $200 million from software, and management anticipates a 10% to 15% growth in annual contract value for 2026, highlighting its strong potential in drug development and market demand.
- Sarepta's Gene Therapy Challenges: Sarepta achieved net product revenue of $1.86 billion in 2025, and despite safety concerns surrounding Elevidys, the company maintains its revenue guidance of $1.2 billion to $1.4 billion for 2026, indicating its ongoing competitiveness in the gene therapy market.
- NRX's Regulatory Progress: NRX Pharmaceuticals is developing treatments for severe depression, and recent FDA feedback indicated no major issues with its preservative-free ketamine, with a potential decision expected this summer, which could significantly increase market attention if approved.
- Improving Macro Environment: Biotech investors are experiencing a more favorable macro environment with stabilizing interest rates and increased FDA activity, providing a fertile backdrop for smaller biotech companies with strong pipelines and differentiated technologies to thrive.
See More
Sarepta to Participate in RBC Healthcare Conference
- Management Participation: Sarepta Therapeutics' senior management will participate in the RBC Capital Markets Global Healthcare Conference on May 20, showcasing the company's leadership in precision genetic medicine, which is expected to attract investor interest.
- Live Webcast Details: The conference will be broadcast live at 8:30 a.m. ET, with investors able to view it on Sarepta's website, and the presentation will be archived for 90 days post-event, ensuring access to critical information.
- Mission Statement: Sarepta is committed to developing precision genetic medicine for rare diseases, particularly leading in Duchenne muscular dystrophy, demonstrating its robust portfolio across muscle, central nervous system, and cardiac diseases.
- Information Posting Channels: The company regularly posts important information in the 'For Investors' section of its website, encouraging investors to visit frequently for updates, thereby enhancing transparency and investor confidence.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
Sarepta Therapeutics Q1 2026 Earnings Call Insights
- Stable Financial Performance: Sarepta reported total net product revenue of $331 million in Q1 2026, with PMO therapies contributing $229 million and ELEVIDYS $102 million, indicating a gradual recovery in profitability following disruptions in 2025.
- Guidance Reaffirmation: Management reiterated its 2026 net product revenue guidance of $1.2 billion to $1.4 billion, while emphasizing that the recovery of ELEVIDYS demand will be a slow process, reflecting a cautious approach to market dynamics.
- Cash Flow and Investments: As of the end of Q1, Sarepta held approximately $748 million in cash and investments, achieving positive cash flow excluding Arrowhead-related payments, demonstrating the company's ability to fund its pipeline without reliance on equity markets.
- Clinical Progress and Regulation: Sarepta is advancing standard approval applications for VYONDYS and AMONDYS, with a PDUFA date expected in February next year, showcasing the company's efforts to strengthen the regulatory standing of its product portfolio.
See More
Biotech Investment Environment Improves
- Improved Market Conditions: Biotech investors are experiencing a friendlier macro environment not seen in years, with stabilizing interest rates, increased FDA activity, and pharmaceutical companies holding billions in cash while facing patent cliffs, creating a favorable backdrop for smaller biotech firms.
- Schrödinger's Growth Potential: Schrödinger (SDGR) is guiding for a 10% to 15% growth in annual contract value (ACV) for 2026, reaching between $218 million and $228 million, showcasing strong growth potential in drug discovery, while reporting total revenue of $256 million for 2025, making it one of the few profitable AI-driven biotech companies.
- Sarepta's Commercial Challenges: Sarepta (SRPT) reported net product revenue of $1.86 billion for 2025, and despite ongoing safety controversies surrounding its Elevidys gene therapy, it maintains a 2026 revenue guidance of $1.2 billion to $1.4 billion, demonstrating a robust commercial foundation in the Duchenne muscular dystrophy market.
- NRX's Regulatory Progress: NRX Pharmaceuticals (NRXP) has received positive feedback from the FDA regarding its lead drug candidate, with a potential decision expected this summer, and while it faces financing and execution risks, its focus on severe depression treatments is attracting increasing investor interest.
See More
Analysis of Biotech Companies' Prospects
- AI-Driven Drug Discovery: Schrödinger reported total revenue of $256 million in 2025, with $200 million from software, and management anticipates a 10% to 15% growth in annual contract value for 2026, highlighting its strong potential in drug development and market demand.
- Sarepta's Gene Therapy Challenges: Sarepta achieved net product revenue of $1.86 billion in 2025, and despite safety concerns surrounding Elevidys, the company maintains its revenue guidance of $1.2 billion to $1.4 billion for 2026, indicating its ongoing competitiveness in the gene therapy market.
- NRX's Regulatory Progress: NRX Pharmaceuticals is developing treatments for severe depression, and recent FDA feedback indicated no major issues with its preservative-free ketamine, with a potential decision expected this summer, which could significantly increase market attention if approved.
- Improving Macro Environment: Biotech investors are experiencing a more favorable macro environment with stabilizing interest rates and increased FDA activity, providing a fertile backdrop for smaller biotech companies with strong pipelines and differentiated technologies to thrive.
See More
Sarepta to Participate in RBC Healthcare Conference
- Management Participation: Sarepta Therapeutics' senior management will participate in the RBC Capital Markets Global Healthcare Conference on May 20, showcasing the company's leadership in precision genetic medicine, which is expected to attract investor interest.
- Live Webcast Details: The conference will be broadcast live at 8:30 a.m. ET, with investors able to view it on Sarepta's website, and the presentation will be archived for 90 days post-event, ensuring access to critical information.
- Mission Statement: Sarepta is committed to developing precision genetic medicine for rare diseases, particularly leading in Duchenne muscular dystrophy, demonstrating its robust portfolio across muscle, central nervous system, and cardiac diseases.
- Information Posting Channels: The company regularly posts important information in the 'For Investors' section of its website, encouraging investors to visit frequently for updates, thereby enhancing transparency and investor confidence.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
Sarepta Therapeutics Q1 2026 Earnings Call Insights
- Stable Financial Performance: Sarepta reported total net product revenue of $331 million in Q1 2026, with PMO therapies contributing $229 million and ELEVIDYS $102 million, indicating a gradual recovery in profitability following disruptions in 2025.
- Guidance Reaffirmation: Management reiterated its 2026 net product revenue guidance of $1.2 billion to $1.4 billion, while emphasizing that the recovery of ELEVIDYS demand will be a slow process, reflecting a cautious approach to market dynamics.
- Cash Flow and Investments: As of the end of Q1, Sarepta held approximately $748 million in cash and investments, achieving positive cash flow excluding Arrowhead-related payments, demonstrating the company's ability to fund its pipeline without reliance on equity markets.
- Clinical Progress and Regulation: Sarepta is advancing standard approval applications for VYONDYS and AMONDYS, with a PDUFA date expected in February next year, showcasing the company's efforts to strengthen the regulatory standing of its product portfolio.
See More
